LOR-2501 | Interleukin Related interleukin-related.com

Product Name :
LOR-2501

Search keywords :
GTI-2501

drugId :
null

Target Vo:
Ribonucleoside-diphosphate reductase M1 chain

Target Vo Short Name :
RRM1

Moa_Name:
Ribonucleoside-diphosphate reductase M1 chain inhibitors

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Aptose

Active Company_Name :

Active Indication_Name:

In Active Indication_Name:
Prostatic Neoplasms

Termination Status :
Phase 2 Clinical

China Termination Status :

Highest Status:
Discontinued

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
PPAR gamma Antibody (YA122)
SOX9 Antibody
RANKL/CD254 Antibody: RANKL/CD254 Antibody is an unconjugated, approximately 35 kDa, rabbit-derived, anti-RANKL/CD254 polyclonal antibody. RANKL/CD254 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, mouse, and predicted: rat, dog background without labeling.

Author: Interleukin Related

Related Posts